

DRUG PRIOR AUTHORIZATION COMMITTEE

March 16, 2017

AGENDA

Department of Natural Resources
Lacharette/Nightingale Rooms
1101 Riverside Drive
Jefferson City, MO

10:00 - 10:05	Welcome, Announcements and Introductions	Chairman
10:05 - 10:10	Minutes Review	Discussion/Approval
10:10 - 10:20	Pharmacy Program/ Budget Update	Steve Calloway/Mitch Ruth
10:20 - 10:25	DUR Update	Steve Calloway

Old Business

10:25 – 10:30	A. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's) <ul style="list-style-type: none">• Hepatitis C Therapy PDL follow-up	Steve Calloway
---------------	--	----------------

New Business

10:30 – 10:35	B. Proposed Actions- New Drug/Product Review (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Fiscal Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Steve Calloway
---------------	---	----------------

10:35 – 10:55	C. <u>Clinical Edits</u>	
---------------	---------------------------------	--

10:55 – 1:00	D. <u>Preferred Drug List (PDL)</u> <ul style="list-style-type: none">I. Benzoyl Peroxide/Clindamycin Topical Agents<ul style="list-style-type: none">• Discussion• Public Hearing• DecisionII. Beta-Adrenergic Agents: Long Acting<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	
--------------	---	--

D. Preferred Drug List (PDL) - continued

- III. Beta-Adrenergic Agents: Nebulized**
 - Discussion
 - Public Hearing
 - Decision
- IV. Beta-Adrenergic Agents: Short Acting**
 - Discussion
 - Public Hearing
 - Decision
- V. COPD Anticholinergics**
 - Discussion
 - Public Hearing
 - Decision
- VI. Cough & Cold Agents**
 - Discussion
 - Public Hearing
 - Decision
- VII. Herpes (Oral) Antivirals**
 - Discussion
 - Public Hearing
 - Decision
- VIII. Inhaled Antibiotics**
 - Discussion
 - Public Hearing
 - Decision
- IX. Inhaled Corticosteroids**
 - Discussion
 - Public Hearing
 - Decision
- X. Intranasal Antihistamines**
 - Discussion
 - Public Hearing
 - Decision
- XI. Intranasal Corticosteroids**
 - Discussion
 - Public Hearing
 - Decision
- XII. Leukotriene Modifiers**
 - Discussion
 - Public Hearing
 - Decision

D. Preferred Drug List (PDL) - continued

XIII. Low Sedating Antihistamines

- Discussion
- Public Hearing
- Decision

XIV. Low Sedating Antihistamine/Decongestant Combinations

- Discussion
- Public Hearing
- Decision

XV. Ophthalmic Antihistamines

- Discussion
- Public Hearing
- Decision

XVI. Ophthalmic Mast Cell Stabilizers

- Discussion
- Public Hearing
- Decision

XVII. Ophthalmic NSAIDS

- Discussion
- Public Hearing
- Decision

XVIII. Ophthalmic Prostaglandin Agonists

- Discussion
- Public Hearing
- Decision

XIX. Ophthalmic Quinolones

- Discussion
- Public Hearing
- Decision

XX. Oral Agents for Psoriasis

- Discussion
- Public Hearing
- Decision

XXI. Oral Antifungals

- Discussion
- Public Hearing
- Decision

XXII. Otic Quinolones

- Discussion
- Public Hearing
- Decision

D. Preferred Drug List (PDL) - continued

- XXIII. Pancreatic Enzymes**
 - Discussion
 - Public Hearing
 - Decision
- XXIV. Self-Injectable Epinephrine Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXV. Topical Agents for Actinic Keratosis**
 - Discussion
 - Public Hearing
 - Decision
- XXVI. Topical Agents for Psoriasis**
 - Discussion
 - Public Hearing
 - Decision
- XXVII. Topical Androgenic Agents**
 - Discussion
 - Public Hearing
 - Decision
- XXVIII. Topical Antifungals**
 - Discussion
 - Public Hearing
 - Decision
- XXIX. Topical Antiparasitics**
 - Discussion
 - Public Hearing
 - Decision
- XXX. Topical Antivirals**
 - Discussion
 - Public Hearing
 - Decision
- XXXI. Topical Immunomodulators (Atopic Dermatitis)**
 - Discussion
 - Public Hearing
 - Decision
- XXXII. Topical Retinoids**
 - Discussion
 - Public Hearing
 - Decision

D. Preferred Drug List (PDL) - continued

XXXIII. Topical Steroids

- Discussion
- Public Hearing
- Decision

XXXIV. Ulcerative Colitis Agents – Oral

- Discussion
- Public Hearing
- Decision

XXXV. Ulcerative Colitis Agents - Rectal

- Discussion
- Public Hearing
- Decision

E. Preferred Drug List Classes for June/July

- i. Process Discussion
- ii. Therapeutic classes/to be announced at meeting

1:00

LUNCH

1:15-1:30

Program Utilization Information - Conduent Update

Luke Boehmer

1:30-1:50

Other Business

- *“Top 25” Drugs by Cost/Claims*
- *Clinical Edit Summary Report*
- *Call Center Statistics*

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, Agenda may move more quickly

NEXT MEETING: June 15, 2017

Missouri Coalition for Community Behavioral Health Care

CEO Room/Lower Level

221 Metro Drive, Jefferson City, MO